UCLA and PreciseDx Announce New Collaboration to Advance AI-Enabled Predictions and Risk Mitigation for Triple-Negative Breast Cancer Recurrence

Sponsored collaboration will focus on evaluating the ability of PreciseBreast™ to accurately predict breast cancer recurrence for those patients with TNBC NEW YORK, April 2, 2024 /PRNewswire/ — PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks